| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The primary targets of Ganoderic acid H are the transcription factors AP-1 and NF-kappaB. It suppresses their signaling, which leads to the inhibition of cancer cell growth and invasive behavior. By inhibiting these transcription factors, it suppresses the secretion of uPA (urokinase-type plasminogen activator), which is involved in cancer cell invasion and metastasis.
|
|---|---|
| ln Vitro |
In vitro, Ganoderic acid H suppresses the growth (cell proliferation and colony formation) and invasive behavior (adhesion, migration, and invasion) of MDA-MB-231 breast cancer cells. It is a potent antitumor agent. Its mechanism involves the inhibition of AP-1 and NF-κB signaling, which are critical for cancer progression.
|
| ln Vivo |
In vivo, Ganoderic acid H has been studied for its antitumor activity. Its ability to suppress the growth and invasive behavior of breast cancer cells in vitro suggests it has significant therapeutic potential for treating invasive breast cancers. However, specific in vivo efficacy data are not extensively documented. Further studies, including animal models of breast cancer, are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
For in vitro cell-based assays, the activity of Ganoderic acid H is evaluated using breast cancer cell lines, such as MDA-MB-231 cells. Cells are treated with the compound, and cell proliferation is measured using colony formation assays or MTT assays. Cell invasion and migration are assessed using transwell or wound-healing assays. The compound's effects on AP-1 and NF-κB signaling are studied using reporter gene assays or by measuring the expression of their target genes.
|
| Cell Assay |
For in vitro cell-based assays, the activity of Ganoderic acid H is evaluated using breast cancer cell lines, such as MDA-MB-231 cells. Cells are treated with the compound, and cell proliferation is measured using colony formation assays or MTT assays. Cell invasion and migration are assessed using transwell or wound-healing assays. The compound's effects on AP-1 and NF-κB signaling are studied using reporter gene assays or by measuring the expression of their target genes.
|
| Animal Protocol |
For in vivo animal studies, Ganoderic acid H is typically administered orally or intraperitoneally. To evaluate its antitumor efficacy against breast cancer, xenograft models using MDA-MB-231 cells can be used. Tumor-bearing mice are treated with the compound, and tumor growth and metastasis are monitored. The compound's effects on AP-1 and NF-κB signaling in tumor tissues can be assessed by immunohistochemistry or Western blotting.
|
| ADME/Pharmacokinetics |
Ganoderic acid H has a molecular weight of 572.69 and a formula of C32H44O9. As a triterpenoid, it is expected to have poor oral bioavailability. Detailed pharmacokinetic parameters are not publicly available.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Ganoderic acid H are limited. As a natural compound from Ganoderma lucidum, it is generally considered to have a favorable safety profile. However, comprehensive toxicological studies have not been published. The compound is used for research purposes only and is not intended for human use.
|
| References | |
| Additional Infomation |
Ganoderic acid H is a triterpenoid compound.
Ganoderic acid H is a research compound with no clinical trial or regulatory approval status. It is a natural product isolated from Ganoderma lucidum and is used as a research tool to study breast cancer and the AP-1 and NF-κB signaling pathways. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C32H44O9
|
|---|---|
| Molecular Weight |
572.6864
|
| Exact Mass |
572.298
|
| CAS # |
98665-19-1
|
| PubChem CID |
73657194
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.25g/cm3
|
| Boiling Point |
710ºC at 760 mmHg
|
| Melting Point |
155-156 °C
|
| Flash Point |
222.5ºC
|
| Index of Refraction |
1.557
|
| LogP |
3.635
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
41
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YCXUCEXEMJPDRZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H44O9/c1-15(11-18(34)12-16(2)28(39)40)19-13-23(37)32(8)24-20(35)14-21-29(4,5)22(36)9-10-30(21,6)25(24)26(38)27(31(19,32)7)41-17(3)33/h15-16,19,21-22,27,36H,9-14H2,1-8H3,(H,39,40)
|
| Chemical Name |
6-(12-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-7,11,15-trioxo-1,2,3,5,6,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl)-2-methyl-4-oxoheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~174.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7461 mL | 8.7307 mL | 17.4615 mL | |
| 5 mM | 0.3492 mL | 1.7461 mL | 3.4923 mL | |
| 10 mM | 0.1746 mL | 0.8731 mL | 1.7461 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
